Stay updated with breaking news from Study Evaluating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Although still recruiting, the first patient was randomized to receive NBI-1070770 for major depressive disorder in a phase 2 trial assessing efficacy, safety, and tolerability.
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo AXS-12 achieved statistically significant remission of cataplexy compared to placebo AXS-12 statistically...
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in...
The combination of GZ17-6.02 and bortezomib reduced of HDAC, and as a result ATG13 phosphorylation was enhanced, BAK levels increased, and BCL-XL levels were reduced.
Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.